Iohexol in patients with previous adverse reactions to contrast media.
Iohexol (Omnipaque) was used for enhancement of brain CT in 17 patients with previous adverse reactions to contrast media. Two of these patients also had cerebral angiography using iohexol. No premedication was given. The only adverse reaction was a skin reaction 24 hours after the iohexol injection, which might have been induced by the contrast medium or treatment with antibiotics. Five of the patients had repeated iohexol injections at different occasions without adverse reactions.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001927:Brain Diseases / Q000000981:diagnostic imaging; D002648:Child; D003287:Contrast Media / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007463:Iodobenzoates / Q000009:adverse effects*; D007472:Iohexol; D007482:Iothalamate Meglumine / Q000009:adverse effects; D008297:Male; D008793:Metrizamide / Q000009:adverse effects; D008794:Metrizoic Acid / Q000009:adverse effects; D008875:Middle Aged; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D014283:Triiodobenzoic Acids / Q000009:adverse effects*
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol; D008794:Metrizoic Acid; D008793:Metrizamide; D007482:Iothalamate Meglumine